[stock_market_widget type=”card” template=”basic2″ assets=”SCLX” realtime=”true” api=”yahoo-finance”]
Every so often, a small company announces a deal so large that it seems to swallow the business making the announcement. That is roughly what happened when Scilex Holding Company (NASDAQ: SCLX), a drugmaker based in Palo Alto, California, said it had signed a binding term sheet to sell $100 million of new stock to a private investment group from Kazakhstan. To put that number in perspective, Scilex carried a stock market value of only about $55 million at the time.
For readers meeting the company for the first time, Scilex sells prescription products meant to treat pain without opioids. Its lineup includes ZTlido, a lidocaine patch for nerve pain that lingers after shingles, along with Gloperba for gout flares and ELYXYB for migraines. It also has several experimental treatments still moving through clinical testing. In plain terms, it is a real business with products on pharmacy shelves, not a research idea waiting to prove itself.
The buyer is iHolding Group LLP, a private investment group based in Almaty, Kazakhstan. Under the term sheet, iHolding would purchase roughly 6.67 million newly created Scilex shares at $15.00 each. That price is the eye-catching part. Scilex stock closed on Thursday at $7.81, so $15.00 amounts to a premium of roughly 90% over the going rate, though it still sits well below the stock’s 52-week high above $21.
A premium of that size is unusual, and it cuts both ways for people who already own the stock. On one side, an outside buyer willing to pay nearly double the market price signals real conviction, and $100 million would be a large amount of fresh cash for a company this size to fund product sales, acquisitions, and partnerships. On the other side, issuing millions of new shares spreads ownership across more hands, which can dilute the stake of current investors. That tension, between badly needed capital and dilution, sits at the heart of the story.
The signed sheet is described as binding, which commits both sides to move forward, but the money changes hands only after several steps are completed: due diligence on the company, the drafting and signing of definitive contracts, and approvals from Scilex’s board, its shareholders, and any relevant regulators. Each of those stages can slow the process or end it all together. Until all of them clear, the $100 million remains a firm intention rather than cash in hand.
This announcement does not arrive in a vacuum. Scilex spent the first half of 2026 stringing together an unusually busy run of deals. It agreed to put $120 million into Datavault AI Inc. (NASDAQ: DVLT) in exchange for a slice of future revenue from a data and computing network, with its cut capped at levels ranging between $250 million and $1.2 billion over time. In June it signed a separate term sheet to buy 837 Bitcoin from that same partner for $50 million. It has also handed shareholders unusual dividends, including tokens tied to a promotional “meme coin” and stock in a spun-off subsidiary.
Seen against that backdrop, the Kazakh investment reads as another attempt to bring in money and remake a company that has struggled on the market. Scilex has been losing money, reporting a steep quarterly loss earlier in the year, and its shares have fallen far from their highs. A large cash infusion could steady the finances, assuming it closes on the stated terms.
What happens next will hinge on the fine print. If the two sides sign definitive agreements and clear their approvals, Scilex could receive a sum that reshapes its balance sheet and its choices. If the talks stall, the company keeps the same challenges it already had, plus the letdown of a headline deal that never closed. The sensible way to read this one is as a real possibility carrying real conditions, worth watching precisely because so much is still unsettled.
